Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus
Viruses · 2024
DOI: 10.3390/v16060843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Megolhubino Terhüja und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA. Hauptthemen laut MEDLINE: Antibodies, Viral, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Vaccines, Virus-Like Particle. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a major cause of severe respiratory tract disease worldwide, and a pediatric vaccine is not available. We generated a filamentous RSV-based virus-like particle (VLP) that presents the central conserved region of the attachment protein G. This was achieved by co-expressing the matrix protein, phosphoprotein, nucleoprotein, and a hybrid fusion protein in which the F ectodomain was replaced with the G central region (GCR). The latter is relatively conserved and contains a receptor binding site and hence is a logical vaccine target. The immunogenicity and efficacy of the resulting VLP, termed VLP-GCR, were examined in mice using intranasal application without adjuvant. VLP-GCR induced substantial anti-N antibody levels but very low anti-G antibody levels, even after three vaccinations. In contrast, a VLP presenting prefusion-stabilized fusion (preF) protein instead of GCR induced both high anti-F and anti-nucleoprotein antibody levels, suggesting that our GCR antigen was poorly immunogenic. Challenge of VLP-GCR-vaccinated mice caused increased weight loss and lung pathology, and both VLPs induced mucus in the lungs. Thus, neither VLP is suitable as a vaccine for RSV-naive individuals. However, VLP-preF enhanced the proportion of preF antibodies and could serve as a multi-antigen mucosal booster vaccine in the RSV-experienced population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Pathobiology, College of Veterinary Medicine, Oklahoma State University, Stillwater, OK 74078, USA.
- Department of Veterinary Sciences and Animal Husbandry, Chitradurga 577502, Karnataka, India.
- RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy, Immunology, and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
- CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India.
ORCID-Profile: Pramila Lamichhane, Timothy A Snider, Antonius G P Oomens
Förderung
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Terhüja, M., Siddappa, M., Lamichhane, P., Meshram, C. D., Snider, T. A., Ritchey, J. W., & Oomens, A. G. P. (2024). Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus. Viruses. https://doi.org/10.3390/v16060843
Vancouver
Terhüja M, Siddappa M, Lamichhane P, Meshram CD, Snider TA, Ritchey JW, et al. Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus. Viruses. 2024. doi:10.3390/v16060843
BibTeX
@article{Terhja2024,
author = {Terhüja, Megolhubino and Siddappa, Manjunath and Lamichhane, Pramila and Meshram, Chetan D and Snider, Timothy A and Ritchey, Jerry W and Oomens, Antonius G P},
title = {Intranasal Vaccination with a Respiratory-Syncytial-Virus-Based Virus-like Particle Displaying the G Protein Conserved Region Induces Severe Weight Loss and Pathology upon Challenge with Wildtype Respiratory Syncytial Virus},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16060843}
}
EUVIMED